RAPT Therapeutics, Inc. (RAPT) EBIT (2020 - 2024)
RAPT Therapeutics' EBIT history spans 5 years, with the latest figure at -$54.5 million for Q4 2024.
- For Q4 2024, EBIT fell 63.97% year-over-year to -$54.5 million; the TTM value through Dec 2024 reached -$136.1 million, down 7.11%, while the annual FY2024 figure was -$136.1 million, 7.11% down from the prior year.
- EBIT for Q4 2024 was -$54.5 million at RAPT Therapeutics, down from -$19.8 million in the prior quarter.
- Across five years, EBIT topped out at -$12.5 million in Q2 2020 and bottomed at -$54.5 million in Q4 2024.
- The 5-year median for EBIT is -$20.3 million (2022), against an average of -$23.6 million.
- The largest YoY upside for EBIT was 41.66% in 2024 against a maximum downside of 63.97% in 2024.
- A 5-year view of EBIT shows it stood at -$13.1 million in 2020, then crashed by 37.82% to -$18.0 million in 2021, then tumbled by 35.47% to -$24.4 million in 2022, then crashed by 35.96% to -$33.2 million in 2023, then crashed by 63.97% to -$54.5 million in 2024.
- Per Business Quant, the three most recent readings for RAPT's EBIT are -$54.5 million (Q4 2024), -$19.8 million (Q3 2024), and -$29.3 million (Q2 2024).